@article{CCO975,
author = {Meng-Chao Wu and Zhao-You Tang and Sheng-Long Ye and Jia Fan and Shu-Kui Qin and Jia-Mei Yang and Min-Shan Chen and Min-Hua Chen and Ming-De Lv and Kuan-Sheng Ma and Yu-Lian Wu and Yi Chen and Guo-Jun Qian and Shi-Chun Lu and Jia-Sheng Zheng and Wen-Bing Sun and Ying-Hua Zou and Hui-Min Liang and Zhi-Yong Huang and Xin-Wei Han and Xiang Jing and Hong-Ming Pan and Tian-An Jiang and Ping Liang and Zheng-Gang Ren and Yao-Jun Zhang},
title = {Expert consensus on local ablation therapies for primary liver cancer},
journal = {Chinese Clinical Oncology},
volume = {1},
number = {1},
year = {2012},
keywords = {},
abstract = {Local ablation therapies are procedures that, guided by medical imaging technology, localize the targeted tumor and then kill tumor tissues through the local application of physical and/or chemical methods. The imaging technology includes ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), and the ablation can be performed through percataneous, laparoscopic, or open surgery. Local ablation has two advantages: First, it can act directly on tumor and thus is highly effective and efficient; second, the efficacy of this treatment is only confined on tumor and its neighboring tissues, with limited effect on human body, and therefore can be repeatedly applied. After the rapid development during the past two decades, local ablation therapy has became the third most promising local treatment (immediately after surgical resection and intervention) for primary liver cancer. Notably, radiofrequency ablation (RFA) is as effective as surgical resection but is simpler and safer in treating small hepatocellular carcinoma (SHCC). Therefore, RFA has been recognized as one of the radical treatment for SHCC and been widely applied in China.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/975}
}